WeissLaw LLP Investigates Dusa Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)-- WeissLaw LLP, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dusa Pharmaceuticals Inc. (NAS: DUSA) arising from its agreement for Dusa to be acquired by Sun Pharmaceuticals Industries Ltd., in a cash deal valued at approximately $230 million. Dusa shareholders will receive $8.00 per share.
WeissLaw LLP is investigating whether Dusa's Board is acting to maximize shareholder value for Dusa's public shareholders in approving this deal and whether the Board engaged in a robust sale process in shopping the company. The $8.00 per share offer price is approximately 15% less than the $9.50 per share price target set by an analyst. If you own Dusa shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at email@example.com or by telephone at (888) 593-4771.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a similar outcome.
KEYWORDS: United States North America New York Texas
The article WeissLaw LLP Investigates Dusa Pharmaceuticals Inc. originally appeared on Fool.com.